The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo.from Moneycontrol Business News https://ift.tt/2BNWgi4
Wednesday, July 8, 2020
AstraZeneca-Merck Lynparza wins European Union approval for pancreatic cancer
The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo.from Moneycontrol Business News https://ift.tt/2BNWgi4
Subscribe to:
Post Comments (Atom)
-
The value had touched a high of 22% of total market capitalisation of listed firms in June 2009, dropping to a low of 5.1% in September 2020...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment